Novavax is a few months away from results for its two lead vaccine programs — and it’s taking steps “to enable us to launch our products as soon as possible post licensure,” CEO Stanley Erck said on a Wednesday earnings call.
{iframe}https://www.bizjournals.com/washington/news/2018/11/08/what-novavax-needs-for-success-as-it-advances.html?ana=e_ae_set1&s=article_du&ed=2018-11-08&u=fQFLvOpMSMnvK7iAcBsVng0eb45ba2&t=1542034772&j=84914151{/iframe}